GINN Panel | InterTabac Dortmund 2026 Moderator: Joel Rubenstein, GINN Panelists: Tomasz Płaska, Chemnovatic; Jack Li, HG Innovation; Shivam Bihani, Satyam’s Sun Products (MYNT) The following transcript has been lightly edited for clarity and readability while preserving the substance and meaning of the speakers’ remarks. Introductions Joel Rubenstein: Hello, everybody. We’re going to shift…
PouchXchange 2026 | Dortmund I feel like Shem gave me a really great intro, as did my colleague there. This is not what I had signed up for, but we’re here! So, I’m hoping, if you allow me 10 minutes, I’ll give you a bit of a view from us at Dholakia Tobacco and RUSH:…
Public health policy depends on informed decision-making. Whether developing regulation, advising patients, or supporting smoking cessation, decisions are only as effective as the information on which they are based. When scientific evidence is misunderstood, selectively interpreted, or communicated without appropriate context, the consequences can extend beyond public debate and influence individual health behaviours. This challenge…
Flavor regulation has become one of the most contested areas in modern nicotine policy. Across the United States, Europe, and global markets at varying stages of regulatory maturity, governments continue debating whether restrictions on flavored nicotine products represent an effective public health intervention or whether overly simplified approaches risk generating consequences their architects did not…
At EVO NXT 2026, the Global Institute for Novel Nicotine hosted a deep dive session examining how evolving EU regulatory frameworks, including the Tobacco Products Directive (TPD3) and the Tobacco Taxation Directive (TTD), are shaping the future of nicotine product governance from policy design to market implementation. The session was chaired by Peter Beckett and…
At EVO NXT 2026, the Global Institute for Novel Nicotine hosted a deep dive session examining how evolving EU taxation frameworks are shaping the regulation, availability, and market dynamics of alternative nicotine products. The session was hosted by Joel Rubenstein and featured contributions from Johan Nissinen, Ciprian Boboi, Vlad Olteanu, and Tomasz Płaska, bringing together…
Recent commentary describing nicotine pouches as “a wolf in sheep’s clothing” reflects legitimate public-health concerns about youth uptake, long-term uncertainty, and nicotine dependence. However, the framing risks obscuring a critical distinction at the heart of modern tobacco control: the difference between absolute risk and relative risk. Nicotine pouches are not risk-free, but the available evidence…
This submission is provided on behalf of the Global Institute for Novel Nicotine (GINN), which advocates for proportionate, science-based regulation that recognises tobacco harm reduction (THR) as a legitimate public health strategy Our focus is on the necessary regulation of nicotine products, specifically nicotine pouches, which are currently available on the UK market but operate…
A new Cochrane systematic review has examined whether oral nicotine pouches can help people stop smoking, vaping, or using other forms of tobacco. While early evidence is promising in showing lower toxicant exposure, the review concludes that more data is needed to determine their long-term impact on cessation outcomes. What the Review Found The Cochrane…